

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	14902	collagen same matrix	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:47
L2	1907	collagen with wound (heal\$3 dress\$3)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:48
L3	1127	I1 and I2	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:48
L4	933	I3 and (crosslink\$4 cross link\$4 link\$4)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:49
L5	51	thermal\$ NEAR3 reconstit\$	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:51
L6	1	I5 with (monosaccharide-aldehyde or monosaccharide aldehyde)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:52
L7	237	I4 and sponge	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:52
L8	178	I7 and (multi-layer collagen layers)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:53
L9	119	I8 and @ad<"20020603"	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:54

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	10195	collagen same (crosslink\$4 cross link\$4 link\$4)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:56
L2	2457	I1 and wound (heal\$3 dress\$3)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:57
L3	1137	sponge near4 matrix	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:58
L4	153	I3 and I2	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:58
L5	120	I4 and (multi-layer collagen layers)	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:59
L6	76	I5 and @ad<"20020603"	US-PGPUB; USPAT	ADJ	ON	2005/12/23 13:59

=> d his

(FILE 'HOME' ENTERED AT 17:16:37 ON 23 DEC 2005)

SET PLURALS ON

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:17:14 ON 23 DEC 2005

L1 QUE COLLAGEN(S) WOUND(1A) HEAL? OR DRESS?

SEA F3-F12, F15-F18

FILE 'USPATFULL, CAPLUS, WPIDS, CABA, PASCAL, MEDLINE, JICST-EPLUS, SCISEARCH, BIOSIS, EMBASE, FSTA, AGRICOLA, USPAT2, FROSTI' ENTERED AT 17:21:39 ON 23 DEC 2005

L2 210067 S L1
L3 16153 S L2 AND MATRIX
L4 6427 S L3 AND (CROSSLINK? OR CROSS LINK?)
L5 771 S L4 AND (MULTI-LAYER OR MULTI?(1W)LAYER?)
L6 82 S L5 AND SPONGE(S)COLLAGEN
L7 80 DUP REM L6 (2 DUPLICATES REMOVED)
L8 28 S L7 AND PY<2003

=> d bib abs 1-28

L8 ANSWER 1 OF 28 USPATFULL on STN
AN 2004:205792 USPATFULL
TI Adipose-derived stem cells and lattices
IN Katz, Adam J., Charlottesville, VA, United States
Llull, Ramon, Mallorca, SPAIN
Futrell, William J., Pittsburgh, PA, United States
Hedrick, Marc H., Encino, CA, United States
Benhaim, Prosper, Los Angeles, CA, United States
Lorenz, Hermann Peter, Los Angeles, CA, United States
Zhu, Min, Los Angeles, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6777231 B1 20040817
WO 2000053795 20000914 <--
AI US 2001-936665 20010910 (9)
WO 2000-US6232 20000310
PRAI US 1999-123711P 19990310 (60)
US 1999-162462P 19991029 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Yucel, Remy; Assistant Examiner: Sandals, William
LREP Mandel & Adriano
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells,

which includes extracellular ***matrix*** material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 28 USPATFULL on STN
AN 2004:174271 USPATFULL
TI Collagen preparation for the controlled release of active substances
IN Roreger, Michael, Neuwied, GERMANY, FEDERAL REPUBLIC OF
PA Lohmann & Rauscher GmbH & Co., KG, Rengsdorf, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6761908 B1 20040713
WO 9528964 19951102 <--
AI US 1996-737111 19961025 (8)
WO 1995-EP1428 19950415
PRAI DE 1994-4414755 19940427
DT Utility
FS GRANTED
EXNAM Primary Examiner: Webman, Edward J.
LREP Wenderoth, Lind & Ponack, L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A collagen preparation for the controlled release of active substances is characterized in that it has mixtures of acid-insoluble collagens with different molecular weight distributions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 28 USPATFULL on STN
AN 2002:288564 USPATFULL
TI Dermal scaffold using alkaline pre-treated chitosan ***matrix*** or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed ***matrix***
IN Son, Young-Sook, Seoul, KOREA, REPUBLIC OF
Youn, Yong-Ha, Bupyeong-ku, KOREA, REPUBLIC OF
Hong, Seok-Il, Seoul, KOREA, REPUBLIC OF
Lee, Seung-Hoon, Seoul, KOREA, REPUBLIC OF
Gin, Yong-Jae, Seoul, KOREA, REPUBLIC OF
Han, Kyu-Bo, Sungnam-si, KOREA, REPUBLIC OF
Kim, Chun-Ho, Seoul, KOREA, REPUBLIC OF
PI US 2002161440 A1 20021031 <--
US 6699287 B2 20040302
AI US 2002-132869 A1 20020425 (10)
RLI Continuation-in-part of Ser. No. US 1999-399547, filed on 20 Sep 1999, PENDING
PRAI KR 1998-39576 19980924
DT Utility
FS APPLICATION
LREP Peter F. Corless, Dike, Bronstein, Roberts & cushman, IP Group of, EDWARDS & ANGELL, LLP, 130 Water Street, Boston, MA, 02109
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are a dermal scaffold comprising alkaline pre-treated free amine-containing chitosan ***matrix***, alkaline pre-treated free amine-containing chitosan and alkaline pre-treated ***collagen*** mixed ***matrix***, or alkaline pre-treated free amine-containing chitosan and alkaline pre-treated ***collagen*** mixed ***matrix*** containing chitosan fabrics, which has excellent ***wound*** ***healing*** effect by constituting microenvironments suitable for migration and proliferation of fibroblasts and vascular cells surrounding the wound to be extremely useful as ***wound*** ***healing*** ***dressings***, and a bioartificial dermis comprising the dermal scaffold and human fibroblasts, particularly useful for ***healing*** broad ***wound*** sites such as burns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 28 USPATFULL on STN
AN 2002:279665 USPATFULL
TI Rapid preparation of stem cell ***matrices*** for use in tissue and organ treatment and repair
IN Chancellor, Michael B., Pittsburgh, PA, UNITED STATES
Huard, Johnny, Wexford, PA, UNITED STATES
Capelli, Christopher, Kenosha, WI, UNITED STATES
Chung, Steve, Pittsburgh, PA, UNITED STATES
Sacks, Michael S., Pittsburgh, PA, UNITED STATES
PI US 2002155096 A1 20021024 <--
AI US 2002-81835 A1 20020222 (10)
PRAI US 2001-271267P 20010223 (60)
DT Utility
FS APPLICATION
LREP MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a rapid method for preparing stem cell and physiologically acceptable ***matrix*** compositions for use in tissue and organ repair. Compared with previous tissue engineering materials, the stem cell- ***matrix*** compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the ***matrix*** material. The stem cell- ***matrix*** compositions as described provide point of service utility for the practitioner, wherein the stem cells and ***matrix*** can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the ***matrix*** composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the ***matrix*** composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 28 USPATFULL on STN
AN 2002:254071 USPATFULL
TI Medicaments based on polymers composed of methacrylamide-modified gelatin
IN Schacht, Etienne, Staden, BELGIUM
Van Den Bulcke, An, Ghent, BELGIUM
Delaey, Bernard, Zingem, BELGIUM
Draye, Jean-Pierre, Chaste, BELGIUM
PA Innogenetics N.V., Ghent, BELGIUM (non-U.S. corporation)
PI US 6458386 B1 20021001 <--
WO 9855161 19981210 <--
AI US 2000-424432 20000128 (9)
WO 1998-EP3320 19980603
PRAI EP 1997-870083 19970603
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Channavajjala, Lakshmi
LREP Howrey Simon Arnold & White, LLP
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1390

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition comprising a biopolymer ***matrix*** comprising ***cross*** - ***linked*** vinyl-derivatives of gelatin, or co-polymerized methacrylamide modified gelatin with vinyl-modified polysaccharides, or ***cross*** - ***linked*** vinyl-substituted polysaccharide and gelatin being physically entrapped in a semi-interpenetrating network. Preferably said polysaccharide comprises dextran or xanthan. The present invention also relates to a wound ***dressing*** or a controlled release device comprising said biopolymer ***matrix***. Preferably said ***matrix*** is in the form of a hydrated film, a hydrated or dry foam, dry fibers which may be fabricated into a woven or non-woven tissue, hydrated or dry microbeads, dry powder, or covered with a semipermeable film so as to control the humidity of the wound covered

with the ***dressing*** , with the permeability chosen so as to maintain this humidity within a therapeutically optimal window.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 28 USPATFULL on STN
AN 2002:246177 USPATFULL
TI Composites for tissue regeneration and methods of manufacture thereof
IN Sherwood, Jill K., Princeton, NJ, United States
Griffith, Linda G., Cambridge, MA, United States
Brown, Scott, Princeton, NJ, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States
(U.S. corporation)
Therics, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 6454811 B1 20020924 <--
AI US 1999-416346 19991012 (9)
PRAI US 1998-103853P 19981012 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: McDermott, Corrine; Assistant Examiner: Stewart, Alvin
LREP Holland & Knight LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 2036

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Composite devices for tissue engineering are provided having a gradient of one or more of the following: materials, macroarchitecture, microarchitecture, or mechanical properties, which can be used to select or promote attachment of specific cell types on and in the devices prior to and/or after implantation. In various embodiments, the gradient forms a transition zone in the device from a region composed of materials or having properties best suited for one type of tissue to a region composed of materials or having properties suited for a different type of tissue. The devices are made in a continuous process that imparts structural integrity as well as a unique gradient of materials in the architecture. The gradient may relate to the materials, the macroarchitecture, the microarchitecture, the mechanical properties of the device, or several of these together. The devices disclosed herein typically are made using solid free form processes, especially three-dimensional printing process (3DP.TM.). The device can be manufactured in a single continuous process such that the transition from one form of tissue regeneration scaffold and the other form of tissue regeneration scaffold have no "seams" and are not subject to differential swelling along an axis once the device is implanted into physiological fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 28 USPATFULL on STN
AN 2002:148263 USPATFULL
TI Adipose-derived stem cells and lattices
IN Katz, Adam J., Charlottesville, VA, UNITED STATES
Llull, Ramon, Mallorca, SPAIN
Futrell, J. William, Pittsburgh, PA, UNITED STATES
Hedrick, Marc H., Encino, CA, UNITED STATES
Benhaim, Prosper, Los Angeles, CA, UNITED STATES
Lorenz, Hermann Peter, Los Angeles, CA, UNITED STATES
Zhu, Min, Los Angeles, CA, UNITED STATES
PA University of Pittsburgh of the Commonwealth System of Higher Education,
Pittsburgh, PA (U.S. corporation)
PI US 2002076400 A1 20020620 <--
AI US 2001-947985 A1 20010906 (9)
RLI Continuation of Ser. No. WO 2000-US6232, filed on 10 Mar 2000, UNKNOWN
PRAI US 1999-123711P 19990310 (60)
US 1999-162462P 19991029 (60)
DT Utility
FS APPLICATION
LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH
STETSON AVENUE, CHICAGO, IL, 60601-6780
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The invention also provides a method of isolating stem cells from adipose tissues. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular ***matrix*** material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 28 USPATFULL on STN
AN 2002:81274 USPATFULL
TI Methods of making conditioned cell culture medium compositions
IN Naughton, Gail K., La Jolla, CA, United States
Mansbridge, Jonathan N., La Jolla, CA, United States
Pinney, R. Emmett, Poway, CA, United States
PA Advanced Tissue Sciences, Inc., La Jolla, CA, United States (U.S. corporation)
PI US 6372494 B1 20020416 <--
AI US 1999-313538 19990514 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine; Assistant Examiner: O'Hara, Eileen B.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2008

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 28 USPATFULL on STN
AN 2002:67498 USPATFULL
TI Compositions and methods for production and use of an injectable naturally secreted extracellular ***matrix***
IN Naughton, Gail K., La Jolla, CA, UNITED STATES
PA Advanced Tissue Sciences, Inc. (U.S. corporation)
PI US 2002038152 A1 20020328 <--
AI US 2001-948379 A1 20010907 (9)
RLI Continuation of Ser. No. US 1996-660787, filed on 6 Jun 1996, PENDING
Continuation-in-part of Ser. No. US 1995-470101, filed on 6 Jun 1995, GRANTED, Pat. No. US 5830708
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 29

ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1292

AB The present invention discloses compositions containing natural human extracellular ***matrices*** and methods for the use thereof. More particularly, the present invention provides compositions and methods for the repair of skin defects using natural human extracellular ***matrix*** by injection.

L8 ANSWER 10 OF 28 USPATFULL on STN

AN 2002:43554 USPATFULL

TI Composition and method for growing, protecting, and healing tissues and cells

IN Petito, George D., Bethlehem, PA, UNITED STATES

Petito, Anita M., Bethlehem, PA, UNITED STATES

PI US 2002025921 A1 20020228 <--

AI US 2001-983274 A1 20011023 (9)

RLI Continuation-in-part of Ser. No. US 1999-360169, filed on 26 Jul 1999, UNKNOWN

DT Utility

FS APPLICATION

LREP Richard C. Litman, LITMAN LAW OFFICES, LTD., P.O. Box 15035, Arlington, VA, 22215

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1216

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition and method for facilitating the growth, protection and healing of tissues and cells in animals and humans. Formulated as a either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or ***sponge***, sprayable solution, topically applied patch with adhesive and reservoir system, an intermediate for coatables such as films and bandages, a ***matrix*** for membranes, or as a ***matrix*** of flexible polymer(s), or delivered as either an orally ingestible liquid, tablet or capsule. The main ingredients are hydrolyzed Type I ***collagen*** having a molecular weight of 1,000-10,000, polysulfated glycosaminoglycans, a hyaluronic acid salt, a glucosamine salt, and optionally, a chelated manganese ascorbate and L-malic acid. In the topical form, the composition is administered to the cleaned wound site where it absorbs exudate, provides a physical barrier to bacterial infestation, reduces pain, and expedites ***wound*** ***healing*** by having chemotactic, hemostatic, bacteriostatic, and other therapeutic benefits. Scars are advantageously reduced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 28 USPATFULL on STN

AN 2002:32517 USPATFULL

TI Compositions and methods for production and use of an injectable naturally secreted extracellular ***matrix***

IN Naughton, Gail K., LaJolla, CA, UNITED STATES

PA Advanced Tissue Sciences, Inc. (U.S. corporation)

PI US 2002019339 A1 20020214 <--

AI US 2001-947131 A1 20010904 (9)

RLI Continuation of Ser. No. US 1998-182822, filed on 29 Oct 1998, GRANTED, Pat. No. US 6284284 Division of Ser. No. US 1996-660787, filed on 6 Jun 1996, PENDING Continuation-in-part of Ser. No. US 1995-470101, filed on 6 Jun 1995, GRANTED, Pat. No. US 5830708

DT Utility

FS APPLICATION

LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 1286

AB The present invention discloses compositions containing natural human extracellular ***matrices*** and methods for the use thereof. More particularly, the present invention provides compositions and methods for the repair of skin defects using natural human extracellular ***matrix*** by injection.

L8 ANSWER 12 OF 28 USPATFULL on STN
AN 2001:147502 USPATFULL
TI Compositions and methods for production and use of an injectable
naturally secreted extracellular ***matrix***
IN Naughton, Gail K., La Jolla, CA, United States
PA Advanced Tissue Sciences, Inc., La Jolla, CA, United States (U.S.
corporation)
PI US 6284284 B1 20010904 <--
AI US 1998-182822 19981029 (9)
RLI Division of Ser. No. US 1996-660787, filed on 6 Jun 1996
Continuation-in-part of Ser. No. US 1995-470101, filed on 6 Jun 1995,
now patented, Pat. No. US 5830708
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Clemens, Karen
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1224
AB The present invention discloses compositions containing natural human
extracellular ***matrices*** and methods for the use thereof. More
particularly, the present invention provides compositions and methods
for the repair of skin defects using natural human extracellular
matrix by injection.

L8 ANSWER 13 OF 28 USPATFULL on STN
AN 2000:137849 USPATFULL
TI Medicaments containing gelatin ***cross*** - ***linked*** with
oxidized polysaccharides
IN Schacht, Etienne, Staden, Belgium
Draye, Jean Pierre, Chaste, Belgium
Delaey, Bernard, Zingem, Belgium
PA Innogenetics N.V., Belgium (non-U.S. corporation)
PI US 6132759 20001017 <--
WO 9741899 19971113
AI US 1998-180057 19981027 (9)
WO 1997-EP2279 19970505
19981027 PCT 371 date
19981027 PCT 102(e) date
PRAI EP 1996-870059 19960503
DT Utility
FS Granted
EXNAM Primary Examiner: Kulkosky, Peter F.
LREP Bierman, Muserlian and Lucas
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a wound ***dressing*** comprising a
biopolymer ***matrix*** comprising gelatin ***cross*** -
linked with an oxidized polysaccharide. Preferably said oxidized
polysaccharide comprises an oxidized dextran or an oxidized xanthan.
Preferably said ***matrix*** is in the form of a hydrated film, a
hydrated or dry foam, dry fibers which may be fabricated into a woven or
non-woven tissue, hydrated or dry microbeads, dry powder; or said
matrix is covered with a semipermeable film, so as to control
the humidity of the wound covered with the ***dressing***, with the
permeability chosen so as to maintain this humidity within a
therapeutically optimal window. A polysulfated polysaccharide with a
M.W. greater than 30,000 kDa is mechanically entrapped during the
formation of said ***matrix***.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 28 USPATFULL on STN
AN 2000:34737 USPATFULL
TI Bioreactor wound ***dressing***
IN Cooke, Randolph L., East Amwell Township, Hunterdon County, NJ, United
States
Stoy, Vladimir A., Princeton Township, Mercer County, NJ, United States
PA Replication Medical, Inc., Rocky Hill, NJ, United States (U.S.
corporation)

PI US 6040493 20000321 <--
AI US 1998-66146 19980424 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Weiss, John G.; Assistant Examiner: Hart, Kelvin
LREP Glynn, Esq., Kenneth P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1173

AB The present invention is a bioreactor wound ***dressing*** which includes a first layer, being a transport layer, in direct contact with a wound. It includes at least one layer of a permeable polymeric media containing, in equilibrium with body fluids, at least 40% by weight of liquid, and is impermeable for infectious agents of any kind and being permeable to water soluble substances having molecular weight up to at least 1000 Daltons. There is a second layer, being a fluid reservoir layer that is adjacent to the transport layer and is capable of containing between 40% and 100% of its volume of an aqueous liquid, wherein the transport layer and reservoir layer are permeably interconnected for aqueous solutions and are in a substantial osmotic equilibrium. The invention also includes a method of wound treatment utilizing the bioreactor wound ***dressing***.

L8 ANSWER 15 OF 28 USPATFULL on STN
AN 1999:36949 USPATFULL
TI Engineering oral tissues
IN Mooney, David J., Ann Arbor, MI, United States
Rutherford, Robert B., Ann Arbor, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)

PI US 5885829 19990323 <--
AI US 1997-864494 19970528 (8)
PRAI US 1996-18450P 19960528 (60)

DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy
LREP Arnold, White & Durkee
CLMN Number of Claims: 109
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 8001

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for regenerating dental and oral tissues from viable cells using ex vivo culture on a structural ***matrix***. The regenerated oral tissues and tissue- ***matrix*** preparations thus provided have both clinical applications in dentistry and oral medicine and are also useful in in vitro toxicity and biocompatibility testing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 28 USPATFULL on STN
AN 1998:134859 USPATFULL
TI Methods for production of a naturally secreted extracellular
matrix
IN Naughton, Gail K., La Jolla, CA, United States
PA Advanced Tissue Sciences, Inc., LaJolla, CA, United States (U.S.
corporation)

PI US 5830708 19981103 <--
AI US 1995-470101 19950606 (8)

DT Utility
FS Granted
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Kerr, Janet M.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1060

AB The present invention is directed to methods for producing naturally secreted human extracellular ***matrix*** material and compositions containing the extracellular ***matrix*** material. The method includes culturing extracellular ***matrix*** -secreting human stromal cells on a biocompatible three-dimensional framework in vitro. After secretion of the extracellular ***matrix*** onto the

framework, the stromal cells are killed and the cells and cellular contents are removed from the framework. The extracellular ***matrix*** material deposited on the framework is collected and further processed to obtain a physiologically acceptable compositions. The compositions of the present invention are useful for the repair of soft tissue and skin defects, including wrinkles and scars.

L8 ANSWER 17 OF 28 USPATFULL on STN

AN 95:45591 USPATFULL

TI ***Multi*** - ***layered*** collagen film compositions for delivery of proteins and methods of using same

IN Song, Suk-Zu, Moorpark, CA, United States

Morawiecki, Andrew, Camarillo, CA, United States

Pierce, Glenn F., Thousand Oaks, CA, United States

Pitt, Colin G., Westlake Village, CA, United States

PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

PI US 5418222 19950523 <--

AI US 1994-267647 19940628 (8)

RLI Continuation of Ser. No. US 1991-716862, filed on 18 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-715165, filed on 14 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner:

Gromet-Degen, Nancy J.

LREP Chambers, Daniel M., Curry, Daniel R.

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to single and ***multiple***
layer collagen films that are useful for improved sustained release delivery of pharmaceuticals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 28 USPATFULL on STN

AN 93:56711 USPATFULL

TI Method of treating a wound

IN Chvapil, Milos, 77 Duck Hill Rd., Tucson, AZ, United States

Barber, Bruce, 77 Duck Hill Rd., Duxbury, MA, United States 02331

PA Barber, Bruce, Duxbury, MA, United States (U.S. individual)

PI US 5227168 19930713 <--

AI US 1992-887357 19920521 (7)

RLI Division of Ser. No. US 1991-742319, filed on 8 Aug 1991, now patented, Pat. No. US 5116620 which is a division of Ser. No. US 1989-439472, filed on 21 Nov 1989, now patented, Pat. No. US 5104660

DT Utility

FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Horne, Leon R.

LREP Crowley, Richard P.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antimicrobial wound ***dressing*** and method of wound treatment, the wound ***dressing*** having a layer of a collagen
dressing material impregnated with lyophilized, stabilized chlorine-containing compounds which generate on activation chlorine dioxide, like a mixture of sodium chlorate and sodium chlorite, and an adjacent layer secured thereto containing a dry, activating amount of an acidic compound, such as citric acid, whereby moisture from the wound activates the dry chlorine moiety to treat the wound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 28 USPATFULL on STN

AN 93:48236 USPATFULL

TI ***Collagen*** ***wound*** ***healing*** ***matrices***

and process for their production

IN Chu, George H., Sunnyvale, CA, United States

Ogawa, Yasushi, Pacifica, CA, United States

McPherson, John M., Hopkinton, MA, United States
Ksander, George, Redwood City, CA, United States
Pratt, Bruce, Union City, CA, United States
Hendricks, Diana, Brea, CA, United States
McMullin, Hugh, San Bruno, CA, United States

PA Collagen Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5219576 19930615 <--
AI US 1991-801732 19911203 (7)

DCD 20070821

RLI Division of Ser. No. US 1990-630299, filed on 19 Dec 1990, now patented,
Pat. No. US 5110604 which is a division of Ser. No. US 1988-213726,
filed on 30 Jun 1988, now patented, Pat. No. US 5024841

DT Utility
FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Kishore, G. S.

LREP Morrison & Foerster

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ***Collagen*** implants that are useful as ***wound***
healing ***matrices*** are characterized by being formed of
collagen fibrils that are not chemically ***cross*** -
linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and
a pore population in which at least about 80% of the pores have an
average pore size of 35 to 250 microns. The implants are capable of
promoting connective tissue deposition, angiogenesis,
reepithelialization, and fibroplasia. The ***wound***
healing ***matrix*** also serves as an effective sustained
delivery system for bioactive agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 28 USPATFULL on STN

AN 92:42546 USPATFULL

TI Antimicrobial wound ***dressing***

IN Chvapil, Milos, 77 Duck Hill Rd., Tucson, AZ, United States

Barber, Bruce A., 77 Duck Hill Rd., Duxbury, MA, United States 02331

PA Barber, Bruce A., Duxbury, MA, United States (U.S. individual)

PI US 5116620 19920526 <--

AI US 1991-742319 19910808 (7)

RLI Division of Ser. No. US 1989-439472, filed on 21 Nov 1989

DT Utility

FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Piccone, Louis
A.

LREP Crowley, Richard P.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 456

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antimicrobial wound ***dressing*** and method of wound treatment,
the wound ***dressing*** having a layer of a collagen
dressing material impregnated with lyophilized, stabilized
chlorine-containing compounds which generate on activation chlorine
dioxide, like a mixture of sodium chlorate and sodium chlorite, and an
adjacent layer secured thereto containing a dry, activating amount of an
acidic compound, such as citric acid, whereby moisture from the wound
activates the dry chlorine moiety to treat the wound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 28 USPATFULL on STN

AN 92:35989 USPATFULL

TI Processes for producing collagen ***matrices*** and methods of using
same

IN Chu, George H., Sunnyvale, CA, United States

Ogawa, Yasushi, Pacifica, CA, United States

McPherson, John M., Framingham, MA, United States

Ksander, George, Redwood City, CA, United States

Pratt, Bruce, Union City, CA, United States

Hendricks, Diana, Brea, CA, United States

McMullin, Hugh, San Bruno, CA, United States

PA Collagen Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5110604 19920505 <--
AI US 1990-630299 19901219 (7)
RLI Division of Ser. No. US 1988-213726, filed on 30 Jun 1988, now patented,
Pat. No. US 5024841
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Kishore, G. S.
LREP Morrison & Foerster
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***Collagen*** implants that are useful as ***wound***
healing ***matrices*** are characterized by being formed of
collagen fibrils that are not chemically ***cross*** -
linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and
a pore population in which at least about 80% of the pores have an
average pore size of 35 to 250 microns. The implants are capable of
promoting connective tissue deposition, angiogenesis,
reepithelialization, and fibroplasia. The ***wound***
healing ***matrix*** also serves as an effective sustained
delivery system for bioactive agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 28 USPATFULL on STN
AN 92:29477 USPATFULL
TI Method of preparing an antimicrobial wound ***dressing***
IN Chvapil, Milos, 77 Duck Hill Rd., Tucson, AZ, United States
Barber, Bruce, 77 Duck Hill Rd., Duxbury, MA, United States 02331
PA Barber, Bruce A., Duxbury, MA, United States (U.S. individual)
PI US 5104660 19920414 <--
AI US 1989-439472 19891121 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Piccone, Louis
A.
LREP Crowley, Richard P.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An antimicrobial wound ***dressing*** and method of wound treatment,
the wound ***dressing*** having a layer of a collagen
dressing material impregnated with lyophilized, stabilized
chlorine-containing compounds which generate on activation chlorine
dioxide, like a mixture of sodium chlorate and sodium chlorite, and an
adjacent layer secured thereto containing a dry, activating amount of an
acidic compound, such as citric acid, whereby moisture from the wound
activates the dry chlorine moiety to treat the wound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 28 USPATFULL on STN
AN 91:50153 USPATFULL
TI ***Multi*** - ***layered***, semi-permeable conduit for nerve
regeneration comprised of type 1 collagen, its method of manufacture and
a method of nerve regeneration using said conduit
IN Li, Shu-Tung, Oakland, NJ, United States
PA Colla-Tec, Incorporated, Plainsboro, NJ, United States (U.S.
corporation)
PI US 5026381 19910625 <--
AI US 1990-561736 19900801 (7)
RLI Division of Ser. No. US 1989-341572, filed on 20 Apr 1989, now patented,
Pat. No. US 4963146
DT Utility
FS Granted
EXNAM Primary Examiner: Pellegrino, Stephen C.; Assistant Examiner: Jackson,
Gary
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1034

AB The present invention is directed to hollow conduits whose walls are comprised of Type I collagen and are characterized by having a ***multi*** - ***layered*** , semi-permeable structure, which conduits are used to promote nerve regeneration across a gap of a severed nerve. Methods of making the nerve regeneration conduit are also disclosed.

L8 ANSWER 24 OF 28 USPATFULL on STN

AN 91:48454 USPATFULL

TI ***Collagen*** ***wound*** ***healing*** ***matrices***

and process for their production

IN Chu, George H., Sunnyvale, CA, United States

Ogawa, Yasushi, Pacifica, CA, United States

McPherson, John M., Hopkinton, MA, United States

Ksander, George, Redwood City, CA, United States

Pratt, Bruce, Union City, CA, United States

Hendricks, Diana, Brea, CA, United States

McMullin, Hugh, San Bruno, CA, United States

PA Collagen Corporation, Palo Alto, CA, United States (U.S. corporation)

PI US 5024841 19910618 <--

AI US 1988-213726 19880630 (7)

DCD 20070821

DT Utility

FS Granted

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Kishore, G. S.

LREP Irell & Manella

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 759

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ***Collagen*** implants that are useful as ***wound***
healing ***matrices*** are characterized by being formed of
collagen fibrils that are not chemically ***cross*** -
linked , and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and
a pore population in which at least about 80% of the pores have an
average pore size of 35 to 250 microns. The implants are capable of
promoting connective tissue deposition, angiogenesis,
reepithelialization, and fibroplasia. The . ***wound***
healing ***matrix*** also serves as an effective sustained
delivery system for bioactive agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 28 USPATFULL on STN

AN 90:79476 USPATFULL

TI ***Multi*** - ***layered*** , semi-permeable conduit for nerve
regeneration

IN Li, Shu-Tung, Oakland, NJ, United States

PA Colla-Tec Incorporated, Plainsboro, NJ, United States (U.S. corporation)

PI US 4963146 19901016 <--

AI US 1989-341572 19890420 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Green, Randall L.; Assistant Examiner: Jackson, Gary

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1180

AB The present invention is directed to hollow conduits whose walls are comprised of Type I collagen and are characterized by having a ***multi*** - ***layered*** , semi-permeable structure, which conduits are used to promote nerve regeneration across a gap of a severed nerve. Methods of making the nerve regeneration conduit are also disclosed.

L8 ANSWER 26 OF 28 USPATFULL on STN

AN 90:38497 USPATFULL

TI Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof

IN Silver, Frederick H., Bangor, PA, United States

Berg, Richard A., Lambertville, NJ, United States
Doillon, Charles J., Edison, NJ, United States
Chernomorsky, Arkady, Elizabeth, NJ, United States
Olson, Robert M., Princeton, NJ, United States
PA University of Medicine and Dentistry of New Jersey, Newark, NJ, United States (U.S. corporation)
PI US 4925924 19900515 <--
AI US 1987-113547 19871026 (7)
RLI Continuation-in-part of Ser. No. US 1986-843828, filed on 26 Mar 1986, now patented, Pat. No. US 4703108, issued on 27 Oct 1987 which is a continuation-in-part of Ser. No. US 1984-593733, filed on 27 Mar 1984, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Nutter, Nathan M.
LREP Weiser & Stapler
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic method for treating pressure ulcers like decubitus ulcers with biodegradable ***collagen*** flake compositions and with biodegradable ***collagen*** ***sponge*** or ***sponge*** -like compositions. The products of the invention includes biodegradable -***collagen*** flake compositions and biodegradable ***collagen*** ***sponge*** or ***sponge*** -like compositions. The products are useful for medical applications, like skin reconstruction, treatment of wounds, especially deep wounds, also in connection with surgery, including cosmetic surgery. The invention also deals with biocompatible synthetic resin ***sponge*** or ***sponge*** -like and flake products for medical and similar applications. The invention contemplates the treatment of human and animal species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 28 USPATFULL on STN
AN 89:36231 USPATFULL
TI Bio compatible and blood compatible materials and methods
IN Woodroof, E. Aubrey, Santa Ana, CA, United States
PA Sterling Drug Inc., New York, NY, United States (U.S. corporation)
PI US 4828561 19890509 <--
AI US 1982-370977 19820422 (6)
RLI Continuation-in-part of Ser. No. US 1979-5319, filed on 22 Jan 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Apley, Richard J.; Assistant Examiner: Cannon, Alan W.
LREP Beehler, Pavitt, Siegemund, Jagger, Martella & Dawes
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Bio- and blood compatible materials are prepared by treating the surface of a substrate to provide reactive primary or secondary amine groups sites which are activated by treatment with a dialdehyde or arylchloride for coupling to a biological in an amount sufficient to provide compatibility. The use of specific substrates, such as a compliant, and elastic material, such as a fabric-elastomer membrane ***matrix***, results in a product having advantageous qualities as a thermal burn ***dressing***, breast prostheses and implants. Detailed procedures and various products are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 28 USPATFULL on STN
AN 89:27504 USPATFULL
TI Bio compatible and blood compatible materials and methods
IN Woodroof, E. Aubrey, Santa Ana, CA, United States
PA Sterling Drug Inc., New York, NY, United States (U.S. corporation)
PI US 4820302 19890411 <--
AI US 1982-392018 19820625 (6)
RLI Continuation-in-part of Ser. No. US 1982-370977, filed on 22 Apr 1982, now abandoned which is a continuation-in-part of Ser. No. US 1979-5319,

filed on 22 Jan 1979, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Apley, Richard J.; Assistant Examiner: Cannon, Alan
LREP Beehler, Pavitt, Siegemund, Jagger, Martella & Dawes
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bio- and blood compatible materials are prepared by treating the surface of a substrate to provide reactive primary or secondary amine groups sites which are activated by treatment with a dialdehyde or arylchloride for coupling to a biological in an amount sufficient to provide compatibility. The use of specific substrates, such as a compliant, and elastic material, such as a fabric-elastomer membrane ***matrix*** , results in a product having advantageous qualities as a thermal burn ***dressing*** , breast prostheses and implants. Detailed procedures and various products are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.14

239.07

STN INTERNATIONAL LOGOFF AT 17:37:56 ON 23 DEC 2005